相关实验视频
Updated: Jun 21, 2025

08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
67.2K
评估炎症性肠病生物标志物的季节性变化
Lidia Neamți1, Tudor Catalin Drugan2, Cristina Drugan1
1Department of Medical Biochemistry.
European journal of gastroenterology & hepatology
|July 8, 2024
概括
炎症性肠病爆发表现出明显的季节性模式,克罗恩病在秋季达到峰值,而性结肠炎在春季达到峰值. 系统性炎症标志物并不总是与肠道炎症水平保持一致.
科学领域:
- 胃肠道学和免疫学
- 时间生物学 时间生物学
- 慢性疾病管理 慢性疾病管理
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病 (CD) 和性结肠炎 (UC),是由遗传,环境和免疫因素影响的慢性疾病.
- 了解IBD恶化和炎症标志物的季节性对于优化患者管理至关重要.
- 以前的研究表明季节和IBD活动之间存在潜在联系,但不同标志物和疾病类型的特定模式需要进一步调查.
研究的目的:
- 研究克罗恩病和性结肠炎患者的炎症标志物和疾病活动的季节性变化.
- 为了确定季节性模式与IBD恶化情节之间的关联.
- 为了比较系统性和肠道炎症标志物的季节性.
主要方法:
- 基于临床,内镜和组织病理学数据分析了284名IBD患者 (CD和UC) 的队列.
- 使用C反应蛋白 (CRP),红细胞沉积率 (ESR) 和奇托里奥西达酶来评估系统性炎症.
- 用便calprotectin测量肠道炎症,以及血清维生素D水平和跨季节评估的综合活性评分.
主要成果:
- 内镜活动在CD (82%) 秋季和UC (95%) 春季达到顶峰. 对于CD (72%) 和UC (87%),春季的组织学活性最高.
- 大多数炎症标志物在冬季较低. 系统性标记物显示出与便calprotectin不同的趋势,并在CD和UC之间有所不同.
- 肠道炎症在CD (784μg/g) 秋季和UC (1269μg/g) 春季达到峰值. CRP和ESR显示了统计学上显著的季节性差异 (P<0.05).
结论:
- 对于克罗恩病和性结肠炎的疾病爆发和炎症标志物演变,存在不同的季节性模式.
- 系统性炎症标志物并不总是反映IBD患者肠道炎症的活性.
- 这些发现强调了在IBD的管理和研究中考虑季节性影响的重要性.
相关概念视频
Inflammatory Bowel Disease II: Crohn's Disease
212
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
212
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160
Chronic Bowel Disorders: Introduction
439
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
439
Irritable Bowel Syndrome I: Introduction
265
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
265
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
128
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
128

